EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin

Shivangi K Patel iD, Taylor Purzycki iD, Alaa Mahmoud iD, John Saldarini iD

Kidney360 · 2026-09 · 7 (9) · 2131-2133

DOI: 10.34067/kid.0000001262 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Kidney360, online erschienen am 15.06.2026. Verfasst von Shivangi K Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Morristown Medical Center, Morristown, New Jersey. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Immunoconjugates. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enfortumab vedotin (EV), an antibody-drug conjugate approved for metastatic urothelial carcinoma, is increasingly recognized to cause severe hyperglycemia and diabetic ketoacidosis (DKA). However, optimal management of EV-associated refractory DKA remains undefined. We describe a 57-year-old man receiving EV and pembrolizumab who developed profound insulin-resistant DKA that persisted despite standard therapy. EV composed of a nectin-4–targeted monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE), which is the primary cause of systemic toxicity. Systemic elimination of MMAE is via metabolism by cytochrome P450 3A4 and biliary/fecal excretion. Tissue exposure is limited via P-glycoprotein efflux pump. Therefore, in the setting of refractory DKA, a pharmacologic enzyme induction was initiated to mitigate further MMAE-induced injury. After initiation of induction alongside continued insulin therapy, resolution of ketoacidosis occurred within 46 hours. This case illustrates a pharmacokinetic-informed approach to EV-associated refractory DKA and highlights how understanding drug metabolism may improve therapeutic outcomes when conventional therapy is insufficient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic KetoacidosisImmunoconjugatesHumansMaleMiddle AgedOligopeptidesInsulin

Stichwörter der Autor:innen

acidosiscancer

Substanzen

Oligopeptidesmonomethyl auristatin EInsulinImmunoconjugates

Autor:innen und Institutionen

  • Department of Nephrology, Morristown Medical Center, Morristown, New Jersey.
  • Department of Internal Medicine, Morristown Medical Center, Morristown, New Jersey.

ORCID-Profile: Shivangi K Patel, Taylor Purzycki, Alaa Mahmoud, John Saldarini

Zitieren

APA

Patel, S. K., Purzycki, T., Mahmoud, A., & Saldarini, J. (2026). Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin. Kidney360, 7(9), 2131-2133. https://doi.org/10.34067/kid.0000001262

Vancouver

Patel SK, Purzycki T, Mahmoud A, Saldarini J. Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin. Kidney360. 2026;7(9):2131-2133. doi:10.34067/kid.0000001262

BibTeX
@article{Patel2026,
  author = {Patel, Shivangi K and Purzycki, Taylor and Mahmoud, Alaa and Saldarini, John},
  title = {Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {9},
  pages = {2131--2133},
  doi = {10.34067/kid.0000001262}
}
Kostenlos starten →